Latest Recruitment News

Page 19 of 50
Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.
Victor Sage
Victor Sage
16 Jan 2026
Cyprium Metals has secured $80 million in funding and advanced key infrastructure works to restart copper production at its Nifty Copper Complex, targeting first cathode output by mid-2026.
Maxwell Dee
Maxwell Dee
16 Jan 2026
Clarity Pharmaceuticals confirms continuation of its SECuRE Phase II trial for Cu-SAR-bisPSMA without protocol changes, reporting encouraging safety and efficacy data in metastatic prostate cancer patients.
Ada Torres
Ada Torres
15 Jan 2026
Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.
Ada Torres
Ada Torres
13 Jan 2026
Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.
Ada Torres
Ada Torres
8 Jan 2026
Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.
Ada Torres
Ada Torres
7 Jan 2026
Estrella Resources appoints Robert Mencel as CEO, transitioning to Managing Director by mid-2026, to spearhead its limestone and manganese projects in Timor-Leste. The leadership reshuffle aims to accelerate development and operational ramp-up.
Maxwell Dee
Maxwell Dee
5 Jan 2026
Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.
Ada Torres
Ada Torres
24 Dec 2025
Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.
Ada Torres
Ada Torres
24 Dec 2025
TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.
Ada Torres
Ada Torres
22 Dec 2025
Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.
Ada Torres
Ada Torres
22 Dec 2025
Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.
Ada Torres
Ada Torres
22 Dec 2025